nodes	percent_of_prediction	percent_of_DWPC	metapath
Milnacipran—Levomilnacipran—ABCB1—colon cancer	0.00891	1	CrCbGaD
Milnacipran—Protein urine present—Methotrexate—colon cancer	0.00562	0.00567	CcSEcCtD
Milnacipran—Upper respiratory tract infection—Fluorouracil—colon cancer	0.00561	0.00566	CcSEcCtD
Milnacipran—Renal failure acute—Capecitabine—colon cancer	0.00529	0.00534	CcSEcCtD
Milnacipran—Libido decreased—Capecitabine—colon cancer	0.00526	0.00531	CcSEcCtD
Milnacipran—Urinary tract infection—Fluorouracil—colon cancer	0.00523	0.00528	CcSEcCtD
Milnacipran—Hot flush—Capecitabine—colon cancer	0.00522	0.00527	CcSEcCtD
Milnacipran—Menopausal symptoms—Capecitabine—colon cancer	0.00517	0.00522	CcSEcCtD
Milnacipran—Hypoaesthesia—Vincristine—colon cancer	0.00516	0.0052	CcSEcCtD
Milnacipran—Hallucination—Vincristine—colon cancer	0.00516	0.0052	CcSEcCtD
Milnacipran—Thirst—Capecitabine—colon cancer	0.00513	0.00518	CcSEcCtD
Milnacipran—Urinary tract disorder—Vincristine—colon cancer	0.00512	0.00516	CcSEcCtD
Milnacipran—Connective tissue disorder—Vincristine—colon cancer	0.00509	0.00514	CcSEcCtD
Milnacipran—Urethral disorder—Vincristine—colon cancer	0.00508	0.00513	CcSEcCtD
Milnacipran—Connective tissue disorder—Irinotecan—colon cancer	0.00496	0.005	CcSEcCtD
Milnacipran—Hyponatraemia—Capecitabine—colon cancer	0.0049	0.00495	CcSEcCtD
Milnacipran—Cystitis noninfective—Methotrexate—colon cancer	0.00489	0.00493	CcSEcCtD
Milnacipran—Disturbance in sexual arousal—Capecitabine—colon cancer	0.00484	0.00489	CcSEcCtD
Milnacipran—Cystitis—Methotrexate—colon cancer	0.00483	0.00488	CcSEcCtD
Milnacipran—Cardiac disorder—Vincristine—colon cancer	0.00481	0.00485	CcSEcCtD
Milnacipran—Hypoaesthesia—Fluorouracil—colon cancer	0.00481	0.00485	CcSEcCtD
Milnacipran—Migraine—Capecitabine—colon cancer	0.00481	0.00485	CcSEcCtD
Milnacipran—Angiopathy—Vincristine—colon cancer	0.0047	0.00474	CcSEcCtD
Milnacipran—Flushing—Irinotecan—colon cancer	0.00468	0.00473	CcSEcCtD
Milnacipran—Cardiac disorder—Irinotecan—colon cancer	0.00468	0.00473	CcSEcCtD
Milnacipran—Mediastinal disorder—Vincristine—colon cancer	0.00467	0.00471	CcSEcCtD
Milnacipran—Irritability—Capecitabine—colon cancer	0.00466	0.0047	CcSEcCtD
Milnacipran—Urinary retention—Capecitabine—colon cancer	0.00464	0.00468	CcSEcCtD
Milnacipran—Angiopathy—Irinotecan—colon cancer	0.00458	0.00462	CcSEcCtD
Milnacipran—Mediastinal disorder—Irinotecan—colon cancer	0.00455	0.00459	CcSEcCtD
Milnacipran—Mental disorder—Vincristine—colon cancer	0.00454	0.00458	CcSEcCtD
Milnacipran—Chills—Irinotecan—colon cancer	0.00453	0.00457	CcSEcCtD
Milnacipran—Bladder pain—Methotrexate—colon cancer	0.00453	0.00457	CcSEcCtD
Milnacipran—Liver function test abnormal—Capecitabine—colon cancer	0.00451	0.00455	CcSEcCtD
Milnacipran—Dry skin—Capecitabine—colon cancer	0.00447	0.00452	CcSEcCtD
Milnacipran—Breast disorder—Capecitabine—colon cancer	0.00441	0.00445	CcSEcCtD
Milnacipran—Flatulence—Irinotecan—colon cancer	0.00433	0.00437	CcSEcCtD
Milnacipran—Abdominal distension—Capecitabine—colon cancer	0.00425	0.00429	CcSEcCtD
Milnacipran—Agitation—Vincristine—colon cancer	0.00415	0.00418	CcSEcCtD
Milnacipran—Angina pectoris—Capecitabine—colon cancer	0.00411	0.00415	CcSEcCtD
Milnacipran—Leukopenia—Vincristine—colon cancer	0.00404	0.00407	CcSEcCtD
Milnacipran—Vision blurred—Fluorouracil—colon cancer	0.00397	0.004	CcSEcCtD
Milnacipran—Neutropenia—Capecitabine—colon cancer	0.00395	0.00398	CcSEcCtD
Milnacipran—Dysuria—Capecitabine—colon cancer	0.00395	0.00398	CcSEcCtD
Milnacipran—Syncope—Irinotecan—colon cancer	0.00394	0.00397	CcSEcCtD
Milnacipran—Renal failure acute—Methotrexate—colon cancer	0.00394	0.00397	CcSEcCtD
Milnacipran—Leukopenia—Irinotecan—colon cancer	0.00393	0.00397	CcSEcCtD
Milnacipran—Upper respiratory tract infection—Capecitabine—colon cancer	0.00392	0.00396	CcSEcCtD
Milnacipran—Convulsion—Vincristine—colon cancer	0.00391	0.00394	CcSEcCtD
Milnacipran—Hypertension—Vincristine—colon cancer	0.00389	0.00393	CcSEcCtD
Milnacipran—Loss of consciousness—Irinotecan—colon cancer	0.00386	0.0039	CcSEcCtD
Milnacipran—Weight decreased—Capecitabine—colon cancer	0.00382	0.00385	CcSEcCtD
Milnacipran—Hypertension—Irinotecan—colon cancer	0.00379	0.00383	CcSEcCtD
Milnacipran—Leukopenia—Fluorouracil—colon cancer	0.00377	0.0038	CcSEcCtD
Milnacipran—Stevens-Johnson syndrome—Capecitabine—colon cancer	0.00373	0.00376	CcSEcCtD
Milnacipran—Infection—Vincristine—colon cancer	0.00366	0.00369	CcSEcCtD
Milnacipran—Urinary tract infection—Capecitabine—colon cancer	0.00366	0.00369	CcSEcCtD
Milnacipran—Convulsion—Fluorouracil—colon cancer	0.00365	0.00368	CcSEcCtD
Milnacipran—Nervous system disorder—Vincristine—colon cancer	0.00361	0.00364	CcSEcCtD
Milnacipran—Thrombocytopenia—Vincristine—colon cancer	0.0036	0.00364	CcSEcCtD
Milnacipran—Haematuria—Capecitabine—colon cancer	0.00359	0.00362	CcSEcCtD
Milnacipran—Chest pain—Fluorouracil—colon cancer	0.00358	0.00361	CcSEcCtD
Milnacipran—Infection—Irinotecan—colon cancer	0.00356	0.00359	CcSEcCtD
Milnacipran—Hyperhidrosis—Vincristine—colon cancer	0.00356	0.00359	CcSEcCtD
Milnacipran—Hepatobiliary disease—Capecitabine—colon cancer	0.00356	0.00359	CcSEcCtD
Milnacipran—Shock—Irinotecan—colon cancer	0.00353	0.00356	CcSEcCtD
Milnacipran—Nervous system disorder—Irinotecan—colon cancer	0.00352	0.00355	CcSEcCtD
Milnacipran—Thrombocytopenia—Irinotecan—colon cancer	0.00351	0.00354	CcSEcCtD
Milnacipran—Anorexia—Vincristine—colon cancer	0.00351	0.00354	CcSEcCtD
Milnacipran—Irritability—Methotrexate—colon cancer	0.00347	0.0035	CcSEcCtD
Milnacipran—Hyperhidrosis—Irinotecan—colon cancer	0.00347	0.0035	CcSEcCtD
Milnacipran—Hypotension—Vincristine—colon cancer	0.00344	0.00347	CcSEcCtD
Milnacipran—Anorexia—Irinotecan—colon cancer	0.00342	0.00345	CcSEcCtD
Milnacipran—Infection—Fluorouracil—colon cancer	0.00341	0.00344	CcSEcCtD
Milnacipran—Hepatitis—Capecitabine—colon cancer	0.00338	0.00341	CcSEcCtD
Milnacipran—Nervous system disorder—Fluorouracil—colon cancer	0.00337	0.0034	CcSEcCtD
Milnacipran—Thrombocytopenia—Fluorouracil—colon cancer	0.00336	0.00339	CcSEcCtD
Milnacipran—Hypoaesthesia—Capecitabine—colon cancer	0.00336	0.00339	CcSEcCtD
Milnacipran—Liver function test abnormal—Methotrexate—colon cancer	0.00336	0.00339	CcSEcCtD
Milnacipran—Tachycardia—Fluorouracil—colon cancer	0.00335	0.00338	CcSEcCtD
Milnacipran—Hypotension—Irinotecan—colon cancer	0.00335	0.00338	CcSEcCtD
Milnacipran—Urinary tract disorder—Capecitabine—colon cancer	0.00334	0.00337	CcSEcCtD
Milnacipran—Insomnia—Vincristine—colon cancer	0.00333	0.00336	CcSEcCtD
Milnacipran—Oedema peripheral—Capecitabine—colon cancer	0.00333	0.00336	CcSEcCtD
Milnacipran—Connective tissue disorder—Capecitabine—colon cancer	0.00332	0.00335	CcSEcCtD
Milnacipran—Urethral disorder—Capecitabine—colon cancer	0.00331	0.00334	CcSEcCtD
Milnacipran—Paraesthesia—Vincristine—colon cancer	0.00331	0.00334	CcSEcCtD
Milnacipran—Breast disorder—Methotrexate—colon cancer	0.00328	0.00331	CcSEcCtD
Milnacipran—Anorexia—Fluorouracil—colon cancer	0.00327	0.0033	CcSEcCtD
Milnacipran—Insomnia—Irinotecan—colon cancer	0.00324	0.00327	CcSEcCtD
Milnacipran—Paraesthesia—Irinotecan—colon cancer	0.00322	0.00325	CcSEcCtD
Milnacipran—Hypotension—Fluorouracil—colon cancer	0.00321	0.00324	CcSEcCtD
Milnacipran—Decreased appetite—Vincristine—colon cancer	0.0032	0.00323	CcSEcCtD
Milnacipran—Dyspnoea—Irinotecan—colon cancer	0.0032	0.00323	CcSEcCtD
Milnacipran—Erythema multiforme—Capecitabine—colon cancer	0.00319	0.00322	CcSEcCtD
Milnacipran—Somnolence—Irinotecan—colon cancer	0.00319	0.00322	CcSEcCtD
Milnacipran—Gastrointestinal disorder—Vincristine—colon cancer	0.00318	0.00321	CcSEcCtD
Milnacipran—Fatigue—Vincristine—colon cancer	0.00317	0.0032	CcSEcCtD
Milnacipran—Eye disorder—Capecitabine—colon cancer	0.00316	0.00318	CcSEcCtD
Milnacipran—Dyspepsia—Irinotecan—colon cancer	0.00316	0.00318	CcSEcCtD
Milnacipran—Constipation—Vincristine—colon cancer	0.00315	0.00318	CcSEcCtD
Milnacipran—Cardiac disorder—Capecitabine—colon cancer	0.00313	0.00316	CcSEcCtD
Milnacipran—Flushing—Capecitabine—colon cancer	0.00313	0.00316	CcSEcCtD
Milnacipran—Decreased appetite—Irinotecan—colon cancer	0.00312	0.00314	CcSEcCtD
Milnacipran—Insomnia—Fluorouracil—colon cancer	0.00311	0.00313	CcSEcCtD
Milnacipran—Gastrointestinal disorder—Irinotecan—colon cancer	0.0031	0.00312	CcSEcCtD
Milnacipran—Fatigue—Irinotecan—colon cancer	0.00309	0.00312	CcSEcCtD
Milnacipran—Paraesthesia—Fluorouracil—colon cancer	0.00308	0.00311	CcSEcCtD
Milnacipran—Constipation—Irinotecan—colon cancer	0.00307	0.00309	CcSEcCtD
Milnacipran—Angiopathy—Capecitabine—colon cancer	0.00306	0.00309	CcSEcCtD
Milnacipran—Dyspnoea—Fluorouracil—colon cancer	0.00306	0.00309	CcSEcCtD
Milnacipran—Somnolence—Fluorouracil—colon cancer	0.00305	0.00308	CcSEcCtD
Milnacipran—Mediastinal disorder—Capecitabine—colon cancer	0.00304	0.00307	CcSEcCtD
Milnacipran—Chills—Capecitabine—colon cancer	0.00303	0.00306	CcSEcCtD
Milnacipran—Dyspepsia—Fluorouracil—colon cancer	0.00302	0.00305	CcSEcCtD
Milnacipran—Gastrointestinal pain—Vincristine—colon cancer	0.00301	0.00304	CcSEcCtD
Milnacipran—Decreased appetite—Fluorouracil—colon cancer	0.00298	0.00301	CcSEcCtD
Milnacipran—Gastrointestinal disorder—Fluorouracil—colon cancer	0.00296	0.00299	CcSEcCtD
Milnacipran—Mental disorder—Capecitabine—colon cancer	0.00296	0.00299	CcSEcCtD
Milnacipran—Malnutrition—Capecitabine—colon cancer	0.00294	0.00297	CcSEcCtD
Milnacipran—Neutropenia—Methotrexate—colon cancer	0.00294	0.00296	CcSEcCtD
Milnacipran—Dysuria—Methotrexate—colon cancer	0.00294	0.00296	CcSEcCtD
Milnacipran—Gastrointestinal pain—Irinotecan—colon cancer	0.00293	0.00296	CcSEcCtD
Milnacipran—Upper respiratory tract infection—Methotrexate—colon cancer	0.00292	0.00295	CcSEcCtD
Milnacipran—Abdominal pain—Vincristine—colon cancer	0.00291	0.00294	CcSEcCtD
Milnacipran—Body temperature increased—Vincristine—colon cancer	0.00291	0.00294	CcSEcCtD
Milnacipran—Flatulence—Capecitabine—colon cancer	0.0029	0.00292	CcSEcCtD
Milnacipran—Erectile dysfunction—Methotrexate—colon cancer	0.00289	0.00292	CcSEcCtD
Milnacipran—Dysgeusia—Capecitabine—colon cancer	0.00288	0.00291	CcSEcCtD
Milnacipran—Abdominal pain—Irinotecan—colon cancer	0.00283	0.00286	CcSEcCtD
Milnacipran—Body temperature increased—Irinotecan—colon cancer	0.00283	0.00286	CcSEcCtD
Milnacipran—Stevens-Johnson syndrome—Methotrexate—colon cancer	0.00278	0.0028	CcSEcCtD
Milnacipran—Vision blurred—Capecitabine—colon cancer	0.00277	0.0028	CcSEcCtD
Milnacipran—Tremor—Capecitabine—colon cancer	0.00275	0.00278	CcSEcCtD
Milnacipran—Urticaria—Fluorouracil—colon cancer	0.00273	0.00275	CcSEcCtD
Milnacipran—Body temperature increased—Fluorouracil—colon cancer	0.00271	0.00274	CcSEcCtD
Milnacipran—Hypersensitivity—Vincristine—colon cancer	0.00271	0.00274	CcSEcCtD
Milnacipran—Haematuria—Methotrexate—colon cancer	0.00267	0.00269	CcSEcCtD
Milnacipran—Hepatobiliary disease—Methotrexate—colon cancer	0.00265	0.00267	CcSEcCtD
Milnacipran—Hypersensitivity—Irinotecan—colon cancer	0.00264	0.00267	CcSEcCtD
Milnacipran—Asthenia—Vincristine—colon cancer	0.00264	0.00267	CcSEcCtD
Milnacipran—Syncope—Capecitabine—colon cancer	0.00264	0.00266	CcSEcCtD
Milnacipran—Leukopenia—Capecitabine—colon cancer	0.00263	0.00266	CcSEcCtD
Milnacipran—Palpitations—Capecitabine—colon cancer	0.0026	0.00262	CcSEcCtD
Milnacipran—Loss of consciousness—Capecitabine—colon cancer	0.00258	0.00261	CcSEcCtD
Milnacipran—Asthenia—Irinotecan—colon cancer	0.00257	0.0026	CcSEcCtD
Milnacipran—Hypertension—Capecitabine—colon cancer	0.00254	0.00256	CcSEcCtD
Milnacipran—Hypersensitivity—Fluorouracil—colon cancer	0.00253	0.00255	CcSEcCtD
Milnacipran—Diarrhoea—Vincristine—colon cancer	0.00252	0.00254	CcSEcCtD
Milnacipran—Hepatitis—Methotrexate—colon cancer	0.00251	0.00254	CcSEcCtD
Milnacipran—Chest pain—Capecitabine—colon cancer	0.0025	0.00253	CcSEcCtD
Milnacipran—Anxiety—Capecitabine—colon cancer	0.00249	0.00252	CcSEcCtD
Milnacipran—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	0.00249	0.00251	CcSEcCtD
Milnacipran—Urinary tract disorder—Methotrexate—colon cancer	0.00248	0.00251	CcSEcCtD
Milnacipran—Urethral disorder—Methotrexate—colon cancer	0.00246	0.00249	CcSEcCtD
Milnacipran—Diarrhoea—Irinotecan—colon cancer	0.00245	0.00248	CcSEcCtD
Milnacipran—Dry mouth—Capecitabine—colon cancer	0.00245	0.00247	CcSEcCtD
Milnacipran—Dizziness—Vincristine—colon cancer	0.00243	0.00246	CcSEcCtD
Milnacipran—Pruritus—Fluorouracil—colon cancer	0.00243	0.00245	CcSEcCtD
Milnacipran—Infection—Capecitabine—colon cancer	0.00238	0.00241	CcSEcCtD
Milnacipran—Erythema multiforme—Methotrexate—colon cancer	0.00238	0.0024	CcSEcCtD
Milnacipran—Dizziness—Irinotecan—colon cancer	0.00237	0.00239	CcSEcCtD
Milnacipran—Shock—Capecitabine—colon cancer	0.00236	0.00238	CcSEcCtD
Milnacipran—Nervous system disorder—Capecitabine—colon cancer	0.00235	0.00237	CcSEcCtD
Milnacipran—Eye disorder—Methotrexate—colon cancer	0.00235	0.00237	CcSEcCtD
Milnacipran—Diarrhoea—Fluorouracil—colon cancer	0.00235	0.00237	CcSEcCtD
Milnacipran—Thrombocytopenia—Capecitabine—colon cancer	0.00235	0.00237	CcSEcCtD
Milnacipran—Tachycardia—Capecitabine—colon cancer	0.00234	0.00236	CcSEcCtD
Milnacipran—Vomiting—Vincristine—colon cancer	0.00234	0.00236	CcSEcCtD
Milnacipran—Cardiac disorder—Methotrexate—colon cancer	0.00233	0.00235	CcSEcCtD
Milnacipran—Skin disorder—Capecitabine—colon cancer	0.00233	0.00235	CcSEcCtD
Milnacipran—Rash—Vincristine—colon cancer	0.00232	0.00234	CcSEcCtD
Milnacipran—Hyperhidrosis—Capecitabine—colon cancer	0.00232	0.00234	CcSEcCtD
Milnacipran—Dermatitis—Vincristine—colon cancer	0.00232	0.00234	CcSEcCtD
Milnacipran—Headache—Vincristine—colon cancer	0.00231	0.00233	CcSEcCtD
Milnacipran—Anorexia—Capecitabine—colon cancer	0.00229	0.00231	CcSEcCtD
Milnacipran—Angiopathy—Methotrexate—colon cancer	0.00228	0.0023	CcSEcCtD
Milnacipran—Vomiting—Irinotecan—colon cancer	0.00228	0.0023	CcSEcCtD
Milnacipran—Dizziness—Fluorouracil—colon cancer	0.00227	0.00229	CcSEcCtD
Milnacipran—Mediastinal disorder—Methotrexate—colon cancer	0.00227	0.00229	CcSEcCtD
Milnacipran—Rash—Irinotecan—colon cancer	0.00226	0.00228	CcSEcCtD
Milnacipran—Dermatitis—Irinotecan—colon cancer	0.00226	0.00228	CcSEcCtD
Milnacipran—Chills—Methotrexate—colon cancer	0.00226	0.00228	CcSEcCtD
Milnacipran—Headache—Irinotecan—colon cancer	0.00225	0.00227	CcSEcCtD
Milnacipran—Hypotension—Capecitabine—colon cancer	0.00224	0.00226	CcSEcCtD
Milnacipran—Mental disorder—Methotrexate—colon cancer	0.0022	0.00222	CcSEcCtD
Milnacipran—Malnutrition—Methotrexate—colon cancer	0.00219	0.00221	CcSEcCtD
Milnacipran—Nausea—Vincristine—colon cancer	0.00219	0.00221	CcSEcCtD
Milnacipran—Vomiting—Fluorouracil—colon cancer	0.00218	0.0022	CcSEcCtD
Milnacipran—Insomnia—Capecitabine—colon cancer	0.00217	0.00219	CcSEcCtD
Milnacipran—Rash—Fluorouracil—colon cancer	0.00217	0.00218	CcSEcCtD
Milnacipran—Dermatitis—Fluorouracil—colon cancer	0.00216	0.00218	CcSEcCtD
Milnacipran—Paraesthesia—Capecitabine—colon cancer	0.00215	0.00217	CcSEcCtD
Milnacipran—Headache—Fluorouracil—colon cancer	0.00215	0.00217	CcSEcCtD
Milnacipran—Dysgeusia—Methotrexate—colon cancer	0.00214	0.00216	CcSEcCtD
Milnacipran—Dyspnoea—Capecitabine—colon cancer	0.00214	0.00216	CcSEcCtD
Milnacipran—Nausea—Irinotecan—colon cancer	0.00213	0.00215	CcSEcCtD
Milnacipran—Dyspepsia—Capecitabine—colon cancer	0.00211	0.00213	CcSEcCtD
Milnacipran—Decreased appetite—Capecitabine—colon cancer	0.00209	0.0021	CcSEcCtD
Milnacipran—Gastrointestinal disorder—Capecitabine—colon cancer	0.00207	0.00209	CcSEcCtD
Milnacipran—Fatigue—Capecitabine—colon cancer	0.00207	0.00209	CcSEcCtD
Milnacipran—Vision blurred—Methotrexate—colon cancer	0.00206	0.00208	CcSEcCtD
Milnacipran—Constipation—Capecitabine—colon cancer	0.00205	0.00207	CcSEcCtD
Milnacipran—Nausea—Fluorouracil—colon cancer	0.00204	0.00206	CcSEcCtD
Milnacipran—Gastrointestinal pain—Capecitabine—colon cancer	0.00196	0.00198	CcSEcCtD
Milnacipran—Leukopenia—Methotrexate—colon cancer	0.00196	0.00198	CcSEcCtD
Milnacipran—Urticaria—Capecitabine—colon cancer	0.00191	0.00192	CcSEcCtD
Milnacipran—Abdominal pain—Capecitabine—colon cancer	0.0019	0.00191	CcSEcCtD
Milnacipran—Body temperature increased—Capecitabine—colon cancer	0.0019	0.00191	CcSEcCtD
Milnacipran—Convulsion—Methotrexate—colon cancer	0.0019	0.00191	CcSEcCtD
Milnacipran—Chest pain—Methotrexate—colon cancer	0.00186	0.00188	CcSEcCtD
Milnacipran—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	0.00185	0.00187	CcSEcCtD
Milnacipran—Infection—Methotrexate—colon cancer	0.00177	0.00179	CcSEcCtD
Milnacipran—Hypersensitivity—Capecitabine—colon cancer	0.00177	0.00178	CcSEcCtD
Milnacipran—Nervous system disorder—Methotrexate—colon cancer	0.00175	0.00177	CcSEcCtD
Milnacipran—Thrombocytopenia—Methotrexate—colon cancer	0.00175	0.00176	CcSEcCtD
Milnacipran—Skin disorder—Methotrexate—colon cancer	0.00174	0.00175	CcSEcCtD
Milnacipran—Hyperhidrosis—Methotrexate—colon cancer	0.00173	0.00174	CcSEcCtD
Milnacipran—Asthenia—Capecitabine—colon cancer	0.00172	0.00174	CcSEcCtD
Milnacipran—Anorexia—Methotrexate—colon cancer	0.0017	0.00172	CcSEcCtD
Milnacipran—Pruritus—Capecitabine—colon cancer	0.0017	0.00171	CcSEcCtD
Milnacipran—Hypotension—Methotrexate—colon cancer	0.00167	0.00168	CcSEcCtD
Milnacipran—Diarrhoea—Capecitabine—colon cancer	0.00164	0.00166	CcSEcCtD
Milnacipran—Insomnia—Methotrexate—colon cancer	0.00162	0.00163	CcSEcCtD
Milnacipran—Paraesthesia—Methotrexate—colon cancer	0.0016	0.00162	CcSEcCtD
Milnacipran—Dyspnoea—Methotrexate—colon cancer	0.00159	0.00161	CcSEcCtD
Milnacipran—Somnolence—Methotrexate—colon cancer	0.00159	0.0016	CcSEcCtD
Milnacipran—Dizziness—Capecitabine—colon cancer	0.00159	0.0016	CcSEcCtD
Milnacipran—Dyspepsia—Methotrexate—colon cancer	0.00157	0.00159	CcSEcCtD
Milnacipran—Decreased appetite—Methotrexate—colon cancer	0.00155	0.00157	CcSEcCtD
Milnacipran—Gastrointestinal disorder—Methotrexate—colon cancer	0.00154	0.00156	CcSEcCtD
Milnacipran—Fatigue—Methotrexate—colon cancer	0.00154	0.00155	CcSEcCtD
Milnacipran—Vomiting—Capecitabine—colon cancer	0.00153	0.00154	CcSEcCtD
Milnacipran—Rash—Capecitabine—colon cancer	0.00151	0.00153	CcSEcCtD
Milnacipran—Dermatitis—Capecitabine—colon cancer	0.00151	0.00153	CcSEcCtD
Milnacipran—Headache—Capecitabine—colon cancer	0.0015	0.00152	CcSEcCtD
Milnacipran—Gastrointestinal pain—Methotrexate—colon cancer	0.00146	0.00147	CcSEcCtD
Milnacipran—Nausea—Capecitabine—colon cancer	0.00143	0.00144	CcSEcCtD
Milnacipran—Urticaria—Methotrexate—colon cancer	0.00142	0.00143	CcSEcCtD
Milnacipran—Abdominal pain—Methotrexate—colon cancer	0.00141	0.00142	CcSEcCtD
Milnacipran—Body temperature increased—Methotrexate—colon cancer	0.00141	0.00142	CcSEcCtD
Milnacipran—Hypersensitivity—Methotrexate—colon cancer	0.00132	0.00133	CcSEcCtD
Milnacipran—Asthenia—Methotrexate—colon cancer	0.00128	0.00129	CcSEcCtD
Milnacipran—Pruritus—Methotrexate—colon cancer	0.00126	0.00128	CcSEcCtD
Milnacipran—Diarrhoea—Methotrexate—colon cancer	0.00122	0.00123	CcSEcCtD
Milnacipran—Dizziness—Methotrexate—colon cancer	0.00118	0.00119	CcSEcCtD
Milnacipran—Vomiting—Methotrexate—colon cancer	0.00114	0.00115	CcSEcCtD
Milnacipran—Rash—Methotrexate—colon cancer	0.00113	0.00114	CcSEcCtD
Milnacipran—Dermatitis—Methotrexate—colon cancer	0.00113	0.00114	CcSEcCtD
Milnacipran—Headache—Methotrexate—colon cancer	0.00112	0.00113	CcSEcCtD
Milnacipran—Nausea—Methotrexate—colon cancer	0.00106	0.00107	CcSEcCtD
